On May 22, Johnson & Johnson (NYSE: JNJ )
hosted an all-day analyst day for its medical device business. This
meeting didn't really offer any major surprises, but did highlight
management's intention to run this business with a focus on returns and
scale and an understanding of where the company can (or cannot) likely
earn attractive returns for shareholders. All told, this update was not
especially bullish for Covidien (NYSE: COV ) or Intuitive Surgical (NASDAQ: ISRG )
, but it may stoke ongoing speculation as to additional areas where
Johnson & Johnson may look to shrink or expand via M&A.
Follow this link for more:
Johnson & Johnson Focusing on Quality Over Quantity
No comments:
Post a Comment